

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number
WO 2004/035828 A2

- (51) International Patent Classification⁷: C12Q 1/68
- (21) International Application Number: PCT/IT2003/000627
- (22) International Filing Date: 14 October 2003 (14.10.2003)
- (25) Filing Language: Italian
- (26) Publication Language: English
- (30) Priority Data:
RM2002A000525 15 October 2002 (15.10.2002) IT
- (71) Applicant (for all designated States except US):
SHARDNA S.P.A. [IT/IT]; Viale Trento 39, I-09123
Cagliari (IT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): PIRASTU, Mario
[IT/IT]; C/O Shardna S.P.A., Piazza Deffenu, 4, I-09125
Cagliari (IT). GIANFRANCESCO, Fernando [IT/IT];
C/O Shardna S.P.A., Piazza Deffenu, 4, I-09125 Cagliari
(IT). ESPOSITO, Teresa [IT/IT]; C/O Shardna S.P.A., Pi-
azza Deffenu, 4, I-09125 Cagliari (IT). OMBRA, Maria,
Neve [IT/IT]; C/O Shardna S.P.A., Piazza Deffenu, 4,
I-09125 (IT).
- (74) Agents: CAPASSO, Olga et al.; De Simone & Partners
S.p.A., Via V. Bellini, 20, I-00198 Roma (IT).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: DIAGNOSTIC AND THERAPEUTIC MEANS FOR KIDNEY STONE RELATED PATHOLOGIES

(57) Abstract: A description is given of a nucleic acid comprising at least one fragment of the human gene ZNF365 or functional portions thereof for use in the diagnosis or treatment of pathologies associated with kidney stones. Appropriate diagnostic kits are also described.

WO 2004/035828 A2

THIS PAGE BLANK (USPTO)

DIAGNOSTIC AND THERAPEUTIC MEANS FOR KIDNEY STONE RELATED PATHOLOGIES

5 The present invention concerns diagnostic and therapeutic means for pathologies associated with kidney stones.

Nephrolithiasis is a common multifactorial disorder characterized by the presence of calculi (stones) in the urinary tract; an important genetic contribution to its pathogenesis has been established; its aetiology is unknown (Jaeger 1996; Curhan et al. 1997; Baggio 1999; Scheinman 1999).
10 Kidney stones are estimated to affect 10% of the population (Serio and Fraioli 1999; Rivers et al. 2000). The major classes of stones are calcium oxalate, calcium phosphate, uric acid, struvite, and cystine. Uric acid nephrolithiasis (UAN) accounts for 20% of all stones. Formation of calculi may occur when the urine becomes overly concentrated with uric acid that
15 may complex to form small crystals and subsequently stones. However, the molecular basis for urate handling in the human kidney is not completely clear.

The authors of the invention have previously identified in patients in the small Sardinian village of Talana a locus of approximately 2.5 cM
20 potentially correlated with UAN and located on chromosome 10q21-q22 (Ombra et al. 2001). However, the locus cannot be used for screening assays on populations, nor for the development of diagnostic assays, nor to define therapeutic agents. It is therefore vital to identify the genomic region associated with the pathology.

25 To identify the region, the authors have extended the search to a larger sample of affected individuals selected from the same study group. Using mapping methods based on sharing of alleles and/or haplotypes identical by descent or on autozygosity, a linkage disequilibrium (LD) block of about 200 kb was found in the Talana population and a core region of 67 kb
30 already associated with UAN. The authors have identified in the associated region a novel gene, called ZNF365, divided into 15 exons spanning a

genomic region of about 300 kb and encoding for at least four different protein isoforms of 407, 333, 462 and 216 amino acids. The encoding sequence for the protein isoform of 216 amino acids was found to reside completely within the core interval of 67 kb. The protein has at least one transmembrane domain and various sites for N-terminal N- and O-glycosylation, suggesting that it may be a membrane protein. Mutation analysis showed that a mutation of a coding nucleotide, which causes a missense in exon 12 (Ala62Thr), is strongly associated with UAN ($p=0.0096$). Moreover, the variant protein has a different secondary structure and might be involved in the aetiology of UAN.

Hence, the object of the present invention is a nucleic acid comprising at least one fragment of the human gene *ZNF365*, in which the fragment encodes for a functional fragment of at least one of the proteins of the *ZNF365* group to be used in the diagnosis of pathologies associated with kidney stones.

A further object of the invention is a nucleic acid comprising at least a fragment of the human gene *ZNF365*, in which the fragment encodes for a functional portion of at least one of the proteins of the *ZNF365* group for therapeutic use in pathologies associated with kidney stones.

A further object of the invention is a method to detect in an individual at least one mutation of the gene encoding for one of the proteins of the *ZNF365* group located on chromosome 10, comprising the phases:

- collection of a sample containing a sufficient quantity of DNA from the aforesaid individual or reproducible in culture;
- isolation of the DNA of the collected sample;
- submission of the isolated DNA to exponential amplification using as an primer pair for the amplification reaction at least two oligonucleotides that are able to amplify at least one fragment of the human gene *ZNF365*, in which the fragment encodes for a functional portion of at least one of the proteins of the *ZNF365* group;

- detection of any mutations in at least one amplified fragment compared with healthy controls.

5 Preferably, the DNA exponential amplification phase is performed using primer pairs able to amplify a part of the fragment encoding the human gene *ZNF365*. More preferably, the DNA exponential amplification phase to amplify a part of the fragment encoding the human gene *ZNF365* comprises the use of the following primer pairs:

Ala62Thr-F: 5' CTC CAC TCC ACC TTT TTA AG 3'

Ala62Thr-R: 5' GCT GAC ATT GGT ACT TAC TG 3'.

10 More preferably, the detection phase of any mutations in at least one amplified fragment compared with healthy controls is performed using direct sequencing. An expert from the field will know which alternative methods come under the range of protection of the invention.

15 A further object of the invention is a diagnostic kit for pathologies associated with kidney stones and comprises:

- at least one pair of oligonucleotide primers for the exponential amplification reaction of at least one fragment of the human gene *ZNF365*, in which a fragment encodes for a functional portion of at least one of the proteins of the *ZNF 365* group;
- 20 - a control DNA from a healthy individual not affected by pathologies associated with kidney stones.

Preferably, the oligonucleotide primer pairs in the kit for performing the amplification reaction are able to amplify a part of the region encoding the *ZNF365* gene.

25 A further object of the invention is a protein belonging to the group of *ZNF365* proteins or a functional portion thereof for use in the diagnosis of pathologies associated with kidney stones.

A further object of the invention is a protein belonging to the group of *ZNF365* proteins or a functional portion thereof for use in the treatment of
30 pathologies associated with kidney stones.

The invention is described below with broad examples and in reference to the following figures:

Figure 1. Physical and transcriptional map of the UAN critical region. Markers of the physical map are indicated vertically above the solid bar representing genomic DNA. Microsatellites used in linkage analysis are D10S1719, D10S1652 and D10S1640. All genes and ESTs located in this region are shown.

Figure 2. SNPs map of the LD block.

Figure 3. Genomic structure of the *ZNF365* gene showing alternative splicing and alternative start sites that generate four different transcripts. Initiation codons (ATG) and stop codons (TAA or TGA) are shown for all isoforms. Two different promoters, a CpG island (P1) and a TATA box (P2) are indicated with arrows. Exons used for each transcript are indicated as colored boxes, while the LD block is indicated as a grey box. Two missense variants found in exons 5 and 12 are shown.

Figure 4. Relationship between the amino acid sequences of *ZNF365* proteins. Grey boxes denote identical amino acids. Solid lines indicate the C2H2 zinc finger domain and coiled-coil fragments. The predicted transmembrane domains are shown in the rectangle.

Figure 5. Results of the association study. The molecular markers used in the study are indicated at the top. The position on the physical map and the association results are indicated for each marker. The different configurations of the associated haplotypes are shown at the bottom.

Figure 6. Secondary structure predictions using the SecStr package are shown. The most probable structures, predicted by three or more methods, are colored black in the joint prediction histograms. (A) The structural prediction for the non associated allele (ala 62). (B) The structural prediction for the uric acid nephrolithiasis susceptibility allele (thr62).

Subjects and methods

Sample collection

All individuals participating in the study came from an isolated village (Talana) in central Sardinia (1200 inhabitants) that is characterized by slow population growth, high endogamy, and high inbreeding (Wright et al. 1999; Angius et al. 2001). The diagnosis of UAN was clinically confirmed by accurate physical examination and by renal ultrasonography. The original patient list included 134 affected subjects. For this study we selected 62 patients (mean age 58.4 years) with severe UAN. All subjects gave signed informed consent, and all samples were taken according to the Helsinki Declaration.

10 SNP genotyping

To find common SNPs in the UAN critical region, we performed an extensive alignment of genomic sequences deposited in public databases using Sequencher software. The screening panel included 10 unrelated persons from the Talana population. PCR amplicons of 800-1000 nt containing the selected putative polymorphisms were designed using the Oligo 4.0 software program. PCR reactions were prepared using 50 ng of genomic DNA template, 0.5 μ M of each PCR-primer, 1.5 mM $MgCl_2$, 0.2 mM of each dNTP, 0.5 U *Taq* polymerase and the buffer recommended by the supplier (Amersham) in a final volume of 25 μ l. Thermo cycling started with a single denaturation step for 2 min at 94°C, followed by 35 cycles of denaturation for 30 sec at 94°C, annealing for 30 sec at Temperature Melting (TM) and extension at 72°C for 45 sec. One final extension step was added for 7 min at 72°C.

Samples were then sequenced using the Big Dye Terminator Ready Reaction Kit (Applied Biosystem). Sequencing reactions were performed on a 9700 Thermal Cycler (Applied Biosystems) for 25 cycles at 95°C for 10 sec, TM for 5 sec and at 60°C for 2 min. After the sequencing, each reaction was isopropanol-precipitated. Sequencing of the products was performed on the ABI prism 3100 Genetic Analyser (Applied Biosystems). Polymorphisms were detected by multiple alignments of sequences using the Autoassembler program (Applied Biosystems).

Mutational analysis of all 15 exons of the identified *ZNF365* gene was performed using PCR, including the intron/exon boundaries.

Genotyping of the single nucleotide polymorphisms was performed by dot-blot hybridisation of the PCR products, comprising the polymorphisms, with short allele-specific oligonucleotides (ASO probes) (Ristaldi et al. 1989).

cDNA clones

ZNF365A (KIAA0844 accession number ABO20651; <http://www.kazusa.or.jp/huge/>) was provided by the Kazusa DNA Research Institute. *ZNF365B* cDNA sequence was obtained by sequencing the cDNA clones 3069791 and 4821260 from the IMAGE Consortium. *ZNF365C* and *ZNF365D* cDNA sequences were obtained by RT-PCR/TOPO-cloning vector (Invitrogen) strategy using primer pairs in different exons of the gene on human kidney RNA (Clontech) and 5'- and 3'-RACE strategy carried out using a human kidney Marathon-Ready cDNA kit.

RNA expression studies

A human multiple-tissue Northern blot (Clontech) was hybridized with *ZNF365A*, *B*, *C* and *D* transcripts. The Northern blot was prehybridized, hybridized, and washed according to the manufacturer's directions (Clontech).

RT-PCR analysis: 0.5 µg of human kidney (Clontech), adrenal gland (Clontech) and blood mRNA were reverse-transcribed in a 50 µl reaction mixture containing 1x RT buffer (20 mM Tris-HCl pH 8.4, 50 mM KCl, 2.5 mM MgCl₂), 10 mM DTT, 0.5 mM dNTP, 0.2 µg of random hexamers (Roche), and 200 units of SuperScript reverse transcriptase (Invitrogen). After 60 min incubation at 37°C, 1 µg of DNase-free RNase was added and incubated 10 min at 37°C. The cDNA was extracted twice with phenol/chloroform/iso-amylalcohol (25:24:1). The cDNA was then precipitated overnight with 1/10 vol of 3 M sodium acetate, pH 5.2, and 2.5 vol of ethanol. 10 ng of each cDNA were used as templates in a 25 µl PCR reaction containing 1x PCR buffer (Amersham), 0.2mM dNTPs, 0.5 units of AmpliTaq polymerase (Amersham), and 0.5 µM each of the primer sequences derived from the

cDNA. Using a DNA Thermal Cycler 9700 (Applied Biosystems), we carried out 40 amplification cycles for 30 sec at 94°C, 30 sec at TM, and 45 sec at 72°C.

5' and 3' RACE strategy was carried out by using 5 µl of Marathon human kidney cDNA (Clontech), 1x PCR buffer (Amersham), 0.2mM dNTPs, 1.0 units of AmpliTaq polymerase (Amersham), and 0.5 µM each of the gene specific primer and AP1 primer (Clontech) in a final volume of 50 µl. 25 amplification cycles were performed for 30 sec at 94°C, 20 sec at TM, and 4 min at 68°C. Nested PCRs were carried out with the same protocol described for the first PCRs using 1/250 of the first PCRs, gene specific primers 2 and AP2 primer (Clontech) in a final volume of 50 µl. 30 amplification cycles were carried out for 30 sec at 94°C, 20 sec at TM, and 4 min at 68°C. Aliquots of the first and second PCR reactions performed with different gene specific primers were run on agarose gel and blotted on nylon membrane according to the manufacturer's directions (Amersham). The membranes were hybridized with a PCR product including exons 2, 3, 4 and 5 of the *ZNF365D* transcript. Positive PCR products were cloned in TOPO-vector (Invitrogen) and sequenced with M13 forward and reverse primers.

RESULTS

Transcriptional map of UAN locus

We obtained a consensus genomic sequence of the 1.1 Mb region, corresponding to the identified 2.5 cM critical interval, by alignment of partial sequences deposited in different databases. The 1.1 Mb interval was found to contain at least 6 novel genes including 2 uncharacterised ones (Figure 1). *MRF-2* (modulator recognition factor 2) gene is encoded by 10 exons and spans a region of about 200 kb. This gene may be an ortholog of mouse Desrt. Homozygous mutants of this gene are developmentally and sexually retarded and have transient immune abnormalities (Lahoud et al. 2001). *RTKN-L* (rhotekin like) gene is a homologue of *RTKN* gene, an inhibitor of rho GTPase activity, located on chromosome 2 (Fu et al. 2000). *RTKN-L* consists of at least 10 exons and spans a region of 75 kb. Given their

biological function, these two genes were not obvious candidates for uric acid nephrolithiasis. The EST 603251916F1 sequence (GenBank Acc. BI603606) belongs to the UniGene cluster Hs.252954. By using the longest mRNA sequence of this UniGene cluster, we found that this gene is split in at least five exons and spans a region of 50 kb. The EST hd42c05.x1 (GenBank Acc. AW511012) exhibits no significant similarity to any ESTs deposited in public databases, suggesting that the gene is present at very low levels in human cells. *KIAA0844* cDNA is derived from the HUGE protein database (Nagase et al. 2000). Finally, the EST 603040095F1 (GenBank Acc. BI822044) encodes for five exons and spans a small region of 15 kb. In the absence of a functional assignment, it is not possible to know which one of these 4 orphan genes may play a role in the pathogenesis of UAN, even though the last EST is the closest to marker D10S1652 already found to be associated with UAN.

Molecular characterization of the UAN susceptibility gene

All previously described genes except the EST 603040095F1 were located outside the LD block and so none of them were further analysed. In order to characterize the 5' and 3' regions of this gene, we performed RT-PCR and RACE strategies starting from the coding region of the EST 603040095F1. An extensive gene spanning a 300 kb region and overlapping the LD block was disclosed. Genomic and cDNAs sequence comparisons showed that the gene consists of 15 exons and includes the EST 603040095F1 inside the critical region (delimited by AFM214zb6) and *KIAA0844* outside it (Figure 1). In the human kidney, where we worked on a complex pattern of alternative splicing and transcriptional start sites, different proteins of 407, 333, 462 and 216 amino acids are generated (Figure 3, Table 1).

Table 1

Exon	(bp)	Exon-Intron junctions	Intron	(bp)
1	264	gagcaagggtGTTCCCCGCG...AACAAAGTCGGgtaagaggcg	1	1721
2	756	cccctcccagGACTTTTAGA...GGAAAGAAGAgtaagtgtg	2	11459
3	181	tgccttcagAGAAGTTGTC...CGGGCACGTGgtgagtcacc	3	10160
4	38	ttccttcagCTTACAGACA...CCAAATGCCTgtatgtatgt	4	750
5	2920	ccctctgtagAAGCCGAGGG...AGCTGTTAAGaattcctgct	5	57322
6	57	ttccttcagAGCTGGAAAG...GGAATTGGAGgtaaagccac	6	20079
7	413	ttatgactagGAGTCTGCGA...TGAGTAATTTatttattaag	7	40174
8	150	agcttgtaaGAAGAGGAAG...CTCCATAACCgtaagaaata	8	102482
9	148	ttgttttagATTTTTGGCC...GCTACTGCAGgtgaatactc	9	20497
10	222	tattttacagGAATTGGCCC...CTGTCTCCAGgtaaatccc	10	10880
11	88	attattctagGTGCTGGAAT...CAAAAACAAGgtaagtcagt	11	436
12	265	ttccacaaagTCAACACATC...TCAATTCAAGgtcatttttg	12	764
13	91	tctgttcagGATTTAGCCA...ACTTTGAGAGgtgggtgtcc	13	9642
14	74	atctctgcagAGAAAGTGTC...TGTGTGATTGgtaagaattt	14	4006
15	1805	gtcttcatagGCAAATTGAC...TACACAGTGTatcacagttt		

5 *ZNF365A transcript* - KIAA0844 cDNA (4158 bp) is encoded by 5 exons and its putative promoter region contains a CpG island. The open reading frame (ORF) of 1224 bp encodes a putative protein of 407 amino acids with a molecular weight of 46558 Da. The N-terminal region of this protein (amino acids 26-51) harbours the classical zinc finger domain of C2H2 family (Figure 4). This domain is found in numerous nucleic acid-binding proteins and has also been used in protein-protein interactions and
 10 membrane associations (Laity et al. 2001). This gene was renamed *ZNF365A* (zinc finger protein 365) by the HUGO Gene Nomenclature Committee. A secondary structure prediction for this protein suggests the presence of four predicted alpha-helical coiled-coil domains frequently used as an oligomerization motif.

15 *ZNF365B transcript* - This transcript of 1671 bp, was identified by EST analysis (associated ESTs are 602688686F1 and UI-H-BW1-amf-e-12-0-UI.s1) and, like *ZNF365A*, was located outside the critical region. Unlike

ZNF365A, this transcript utilizes different exons 4 and 5 (Figure 3). The encoded protein of 333 amino acids is identical to the *ZNF365A* protein in the N-terminal region (exons 1-3) containing the zinc finger domain and coiled-coil fragments but it is different at the C-terminal (Figure 4).

5 *ZNF365C transcript* - *ZNF365C* was isolated by RT-PCR analysis using different combinations of primers anchored in different exons of the gene. This transcript of 3376 bp overlaps the critical region. It uses the first 4 exons and the same CpG island promoter of *ZNF365B* transcript outside the critical region and 4 different exons (9,13,14 and 15) located in the LD block
10 (Figure 3). The encoded protein of 462 amino acids is similar to the *ZNF365B* protein but has a different C-terminal region. Computer-assisted analysis of this isoform based on transmembrane domain prediction revealed at least two membrane-spanning domains in this novel C-terminal region from amino acid 344 to 395, suggesting that it may be an integral membrane protein
15 (Figure 4).

ZNF365D transcript - *ZNF365D* spans a region of about 150 kb and uses its own specific TATA-box promoter. All coding exons of this transcript are completely included in the LD block associated with UAN (Figure 3). Full-length cDNA was obtained by 5' and 3' RACE strategies. The composite
20 cDNA sequence of 2695 bp encodes a protein of 216 amino acids that is completely different from the proteins encoded by *ZNF365A* and *B*, but identical to the *ZNF365C* protein in the C-terminal region (Figure 4). Prediction analysis revealed a strong transmembrane domain in this isoform at positions 126-149, suggesting that, like *ZNF365C*, it could be an integral
25 membrane protein with N-termini outside the cell. In this non cytosolic portion several potential modification sites were detected, including possible N and O-linked glycosylation sites (at Asn-20, Asn-82, Thr-88, Thr-89, Ser-90, Ser-91, Ser-93, Thr-97), suggesting that this outer-membrane protein portion may be glycosylated. In addition, several cysteine residues that may participate in
30 disulfide bond formation were disclosed at positions 14, 27, 112, 113, 142, 183, and 207. Finally, three possible protein kinase C sites at Ser-163, Ser-

165, Ser-167 at C-termini were shown (Figure 4). These latter consensus sites may be located intracellularly.

The protein isoforms of 407, 333, 462 and 216 amino acids revealed no significant homology to other proteins deposited in public databases, suggesting that they could be a new class of undisclosed proteins. *ZNF365B*, *C*, *D*, revealed no signals by northern analysis, but RT-PCR assays showed low levels of expression in the blood, the kidney and the adrenal gland tissues. In particular, *ZNF365D* transcript was expressed in blood tissues 10 times less than GAPDH gene expression in a real-time PCR experiment.

A specific *ZNF365D* allele with an altered structure

Sequencing of all exons of *ZNF365* and part of the intronic regions was performed on eight selected patients carrying the putative high-risk nephrolithiasis susceptibility haplotype. Two variants causing missense in the exon 5 (*ZNF365A* transcript) were identified that lead to serine/alanine amino acid substitution (variant Ser337Ala) and in the exon 12 (*ZNF365D* transcript) that lead to alanine/threonine amino acid substitution (variant Ala62Thr) (Figure 3). Moreover, the authors identified a number of polymorphisms in the UTR regions and in intronic regions of the gene.

An analysis was performed to determine whether the presence of these alleles confers increased risk to UAN. A comparison of allelic frequencies in UAN patients and controls showed a strong association between UAN and variant Ala62Thr ($p=0.0096$; empirical $p=0.0052$). When haplotype frequencies in cases and controls including the identified variants were compared, we observed increased evidence of association with UAN for the various haplotype configurations ($p=0.0205$; $p=0.0239$; $p=0.0280$; $p=0.0306$) (Figure 5).

Computer-assisted analysis strongly predicted that the ala62thr variation induces secondary structural alteration of the *ZNF365D* protein in the third alpha helical loop (Figure 6). These results suggest that the effect of threonine causes a significant conformational change that may have

important implications for the biological function of this protein or its interaction with other proteins.

REFERENCES

- Angius A, et al. (2001) Archival, demographic and genetic studies
5 define a Sardinian sub-isolate as a suitable model for mapping complex traits. *Hum Genet* 109:198-209.
- Baggio B (1999) Genetic and dietary factors in idiopathic calcium nephrolithiasis: what do we have, what do we need? *J Nephrol* 12:371-374.
- Berger B, et al (1995) Predicting Coiled Coils by Use of Pairwise
10 Residue Correlations. *Proc Natl Acad Sci USA* 92:8259-8263.
- Bourgain C, et al (2000) Search for multifactorial genes in founder populations. *Ann Hum Genet* 64: 255-265.
- Burgess AW, Ponnuswamy PK, Scheraga HA (1974) Analysis of conformations of aminoacid residues and prediction of backbone topography
15 in proteins. *Isr J Chem* 12: 239-286.
- Chou P, Fasman GD (1978) Prediction of the secondary structure of proteins from their aminoacid sequence. *Adv Enzymol* 47:45-148.
- Cserzo M, et al (1997) Prediction of transmembrane alpha-helices in prokaryotic membrane proteins: the dense alignment surface method. *Protein*
20 *Eng* 10: 673-676.
- Curhan GC, et al (1997) Family history and risk of kidney stones. *J Am Soc Nephrol* 8:1568-1573.
- Daly MJ, et al (2001) High-resolution haplotype structure in the human genome. *Nat Genet* 29:229-232.
- 25 Dufton MJ, Hider, RC (1977) Snake toxin secondary structure predictions: structure activity relationships. *J Mol Biol* 115:117-193.
- Enomoto A, et al (2002) Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. *Nature* 417: 447 - 452.
- Fu Q, et al (2000) Molecular cloning, expression characterization, and
30 mapping of a novel putative inhibitor of rho GTPase activity, RTKN, to D2S145-D2S286. *Genomics* 328-332.

Garnier J, Osguthorpe DJ, Robson B (1978) Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. *J Mol Biol* 120:97-120.

5 Goldstein AM, et al (2001) A common founder for the V126D CDKN2A mutation in seven North American melanomaprone families. *Br J Cancer* 85:527-530.

Hedrick PW (1987) Gametic disequilibrium measures: proceed with caution. *Genetics* 117:331-341.

10 Hofmann K and Stoffel W (1993) TMbase - A database of membrane spanning proteins fragments *Biol. Chem. Hoppe-Seyler* 374,166.

Jaeger P (1996) Genetic versus environmental factors in renal stone disease. *Curr Opin Nephrol Hypertens* 5:342-346.

15 Jeffreys AJ, Ritchie A, Neumann R (2000) High resolution analysis of haplotype diversity and meiotic crossover in the human TAP2 recombination hotspot. *Hum Mol Genet* 9: 725-733.

Kruglyak L, Daly MJ, Lander ES (1995) Rapid multipoint linkage analysis of recessive traits in nuclear families, including homozygosity mapping. *Am J Hum Genet* 56:519-527.

20 Lahoud MH, et al (2001) Gene targeting of Desrt, a novel ARID class DNA-binding protein, causes growth retardation and abnormal development of reproductive organs. *Genome Res* 11(8): 1327-1334.

Laity JH, Lee BM, Wright PE (2001) Zinc finger proteins: new insights into structural and functional diversity. *Curr Opin Struct Biol* 11:39-46.

25 Lim V I (1974) Algorithms for prediction of alpha-helical and beta-structural regions in globular proteins. *J Mol Biol* 88:873-894.

Lupas A, Van Dyke M, Stock J (1991) Predicting Coiled Coils from Protein Sequences *Science* 252:1162-1164.

Kruglyak L (1997) What is significant in whole-genome linkage disequilibrium studies? *Am J Hum Genet* 61: 810-812.

30 Malashkevich VN, et al (1996) The crystal structure of a five-stranded coiled coil in COMP: a prototype ion channel? *Science* 274:761-765.

Nagano K. (1977) Logical analysis of the mechanism of protein folding. IV Supersecondary structures. J. Mol. Biol. 109:235-250.

Nagase T, et al (1998) Prediction of the Coding Sequences of Unidentified Human Genes. XII. The Complete Sequences of 100 New cDNA Clones from Brain Which Code for Large Proteins in vitro. DNA Research 5: 355-364.

Ombra MN, et al (2001) Identification of a new candidate locus for uric acid nephrolithiasis. Am J Hum Genet 68: 1119-29.

Pasquier C, Hamodrakas SJ (1999) An hierarchical artificial neural network system for the classification of transmembrane proteins. Protein Eng 12: 631-634.

Patil N, et al (2001) Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science 294:1719-1723.

Peltonen L, Palotie A, Lange K (2000) Use of population isolates for mapping complex traits. Nat Genet 1: 182-90.

Persson B, Argos P. (1996) Topology prediction of membrane proteins. Protein Sci 5: 363-371.

Ristaldi MS, et al (1989) Prenatal diagnosis of beta-thalassaemia in Mediterranean populations by dot blot analysis with DNA amplification and allele specific oligonucleotide probes. Prenat Diagn 9(9):629-38.

Rivers K, Shetty S, Menon M (2000) When and how to evaluate a patient with nephrolithiasis. Urol Clin North Am 27: 203-213.

Roch-Ramel F, Guisan B (1999) Renal transport of urate in humans. News Physiol Sci 14: 80-84.

Scheinman SJ (1999) Nephrolithiasis. Semin Nephrol 19:381-388.

Serio A, Fraioli A (1999) Epidemiology of nephrolithiasis. Nephron Suppl 81:26-30.

Sobel E, Lange K (1996) Descent graphs in pedigree analysis: applications to haplotyping, location scores, and marker-sharing statistics. Am J Hum Genet 58:1323-1337.

Tabor HK, Risch NJ, Myers RM (2002) Candidate-gene approaches for studying complex genetic traits: practical considerations. *Nat Rev Genet* 3: 391-397.

5 Terwilliger JD (1995) A powerful likelihood method for the analysis of linkage disequilibrium between trait loci and one or more polymorphic marker loci. *Am J Hum Genet* 56:777-787.

Terwilliger JD, et al (1998) Mapping in small populations with no demographic expansion. *Hum Hered* 48:138-154.

10 von Heijne G (1992) Membrane Protein Structure Prediction, Hydrophobicity Analysis and the Positive-inside Rule. *J Mol Biol* 225: 487-494.

Wright AF, Carothers AD, Pirastu M (1999) Population choice in mapping genes for complex diseases. *Nat Genet* 23:397-404.

15 Wu X, Lee CC, Muzny DM, Caskey CT (1989) Urate oxidase: Primary structure and evolutionary implications. *Proc Natl Acad Sci USA* 86, 9412-9416.

Wu X, Muzny DM, Lee CC, Caskey CT (1992) Two independent mutational events in the loss of urate oxidase. *J Mol Evol* 34, 78-84.

CLAIMS

1. Nucleic acid comprising at least one fragment of the human gene *ZNF365* in which said fragment encodes for a functional portion of at least one of the proteins of the *ZNF365* group for use in the diagnosis of pathologies associated with kidney stones.
2. Nucleic acid comprising at least one fragment of the human gene *ZNF365* in which said fragment encodes for a functional portion of at least one of the proteins of the *ZNF365* group for use in the treatment of pathologies associated with kidney stones.
3. Method to detect in an individual at least one mutation in the gene encoding for one of the proteins of the human *ZNF365* group located on chromosome 10 and comprising the phases:
 - collection of a sample containing a sufficient quantity of DNA from the aforesaid individual or reproducible in culture;
 - isolation of the DNA of said sample;
 - submission of the isolated DNA to exponential amplification using as an primer pair for amplification reaction at least two oligonucleotides that are able to amplify at least one fragment of the human gene *ZNF365*, in which said fragment encodes for a functional portion of at least one of the proteins of the *ZNF365* group;
 - detection of any mutations in at least one amplified fragment compared with healthy controls.
4. Method according to claim 3 in which the DNA exponential amplification phase is performed using primer pairs for the amplification reaction that is able to amplify a part of the fragment encoding the human gene *ZNF365*.
5. Method according to claim 4 in which the DNA exponential amplification phase to amplify a part of the fragment encoding the human gene *ZNF365* comprises the use of the following primer pairs:
 - Ala62Thr-F: 5' CTC CAC TCC ACC TTT TTA AG 3'
 - Ala62Thr-R: 5' GCT GAC ATT GGT ACT TAC TG 3'.

6. Method according to claims 3, 4, and 5 in which the detection phase of any mutations in at least one amplified fragment compared with healthy controls is performed using direct sequencing.
7. Diagnostic kit for pathologies associated with kidney stones to perform
5 the method according to claims 3, 4, 5 and 6, that comprises:
 - at least one pair of oligonucleotide primers for the exponential amplification reaction of at least one fragment of the human gene *ZNF365*, in which said fragment encodes for a functional portion of at least one of the proteins of the *ZNF 365* group;
 - 10 - a control DNA from a healthy individual not affected by pathologies associated with kidney stones.
8. Kit according to claim 7 in which oligonucleotide primer pairs in the kit for performing the amplification reaction are able to amplify a part of the region encoding the gene *ZNF365*.
9. Protein belonging to the group of the *ZNF365* proteins or a functional
15 portion thereof for use in the diagnosis of pathologies associated with kidney stones.
10. Protein belonging to the group of the *ZNF365* proteins or a functional
20 portion thereof for use in the treatment of pathologies associated with kidney stones.

THIS PAGE BLANK (USPTO)

1/6





Figure 1

THIS PAGE BLANK (USPTO)

Figure 2



THIS PAGE BLANK (USPTO



SUBSTITUTE SHEET (RULE 26)

JC13 Rec'd PCT/PTO 15 APR 2003

THIS PAGE BLANK (USPTO)

C2H2 domain		
ZNF365A	MQQAFESRYPMQESFENVAVCLPRLCPRCGGDHTFRSLSSRAHLEFSHSYEERTLLTKCSLEPSLRDLDLVTSSELLKPKGLQSSGNVVKQPSYVN	100
ZNF365B	MQQAFESRYPMQESFENVAVCLPRLCPRCGGDHTFRSLSSRAHLEFSHSYEERTLLTKCSLEPSLRDLDLVTSSELLKPKGLQSSGNVVKQPSYVN	100
ZNF365C	MQQAFESRYPMQESFENVAVCLPRLCPRCGGDHTFRSLSSRAHLEFSHSYEERTLLTKCSLEPSLRDLDLVTSSELLKPKGLQSSGNVVKQPSYVN	100
		coiled
ZNF365A	LYSISHEHSKDRKPFEEWAERPVSXVQTYTAMDLDHDSLDGHSGLPTSDTKASFEAHVPEKENRPMVEADRTIEKRIDKLTKELAQKTAELLEVRAA	200
ZNF365B	LYSISHEHSKDRKPFEEWAERPVSXVQTYTAMDLDHDSLDGHSGLPTSDTKASFEAHVPEKENRPMVEADRTIEKRIDKLTKELAQKTAELLEVRAA	200
ZNF365C	LYSISHEHSKDRKPFEEWAERPVSXVQTYTAMDLDHDSLDGHSGLPTSDTKASFEAHVPEKENRPMVEADRTIEKRIDKLTKELAQKTAELLEVRAA	200
		coil
ZNF365A	EVQLTQKQEVORRRERALNRQVDVAVEMIAVLRQRLTESEEEELRKBEENVATENHFFLEAAAEKEVQKARLODETEENLLQRVLEAEKQLEIYQSQQASGF	300
ZNF365B	EVQLTQKQEVORRRERALNRQVDVAVEMIAVLRQRLTESEEEELRKBEENVATENHFFLEAAAEKEVQKARLODETEENLLQRVLEAEKQLEIYQSQQASGF	300
ZNF365C	EVQLTQKQEVORRRERALNRQVDVAVEMIAVLRQRLTESEEEELRKBEENVATENHFFLEAAAEKEVQKARLODETEENLLQRVLEAEKQLEIYQSQQASGF	300
ZNF365D	MSALGQITITVSRWCWNTERNQTDKNPCLHGAYLQLRETIVKNKSTHLKKPLMKQA	54
		*
ZNF365A	VRDLSGHVLTIDISSNRKPKGLSRGPHSVCNHPDLKSHFHPKGRNHLKAKODRASMQPAKAIHEQAESSRDLCRPPKKGELLGFGKGNIRPKMAKKKP	400
ZNF365B	VRDLSGHVSWKAGEARLVCONDIHEEESAIVE	333
ZNF365C	VRDLSGHVSWKAGEARLVCONDIHEEIEFGHINHLGSLKDSHCLVFLQAPPVPWIIILASFLMWILGNPWTSSSTATAGFSQIWLFRPCGGTEHHNEKDVLT	400
ZNF365D	PPWKDHLAFQPLHPAERKTQVWRWQSGNSSDLETTSSASPNWPTGNSRDVVLNTLAESCCGLSELITAPPYAGVSIQGFQIWLFRPCGGTEHHNEKDVLT	154
		Transmembrane domains
ZNF365A	TAIVNII	407
ZNF365C	GIQDFFERESVTSQSRNISLLTGLQONCVIGKLTIDLTTEHLLGVRHGVICFPWGLPSSS	462
ZNF365D	GIQDFFERESVTSQSRNISLLTGLQONCVIGKLTIDLTTEHLLGVRHGVICFPWGLPSSS	216
		# # #

Figure 4

THIS PAGE BLANK (USPTO)

Marcatore	D10S1719	SNP NG3	SNP 9	SNP 10	SNP 11	Ala627T/C	SNP AV70	D10S1652	PSNP 3A	SNP AV72	SNP 14	AFM214zb6	SNP N	SNP 1	SNP 7	AFM234wc5	D10S1640	
Posizione (Kb)	-	4	12	30	46	83	85	90	100	113	120	175	216	260	527	850	1055	
val. p ^a	n.s.	n.s.	n.s.	n.s.	n.s.	0,0123	n.s.	0,0006	0,0123	n.s.	n.s.	0,0213	n.s.	n.s.	n.s.	n.s.	n.s.	
val. p ^b empirico ^b	n.s.	n.s.	n.s.	n.s.	n.s.	0,0085	n.s.	0,0004	0,0073	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	
val. p ^c	n.s.	n.s.	n.s.	n.s.	n.s.	0,0096	n.s.	0,0009	0,0145	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	
val. p ^d empirico ^d	n.s.	n.s.	n.s.	n.s.	n.s.	0,0051	n.s.	0,0031	0,0075	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	
val. p ^e empirico ^e (analisi aplotipo)	0,0205						0,0239						0,0280					


Figure 5

0013 Rec'd PCT/PTO 15 APR 2005

THIS PAGE BLANK (USPTO)

6/6

A



B




Figure 6

THIS PAGE BLANK (USPTO)

shardna.ST25.txt
SEQUENCE LISTING

<110> SHARDNA. SpA

<120> Diagnostic and therapeutic means for kidney stone related pathologies

<130> 30183

<160> 36

<170> PatentIn version 3.1

<210> 1

<211> 20

<212> DNA

<213> Artificial

<400> 1
ctccactcca cctttttaag

20

<210> 2

<211> 20

<212> DNA

<213> Artificial

<400> 2
gctgacattg gtacttactg

20

<210> 3

<211> 20

<212> DNA

<213> Homo sapiens

<400> 3
gagcaagggg gtccccgcg

20

<210> 4

shardna.ST25.txt

<211> 20

<212> DNA

<213> Homo sapiens

<400> 4

aacaagtcgg gtaagaggcg

20

<210> 5

<211> 20

<212> DNA

<213> Homo sapiens

<400> 5

cccctcccag gacttttaga

20

<210> 6

<211> 20

<212> DNA

<213> Homo sapiens

<400> 6

ggaaagaaga gtaagtgttg

20

<210> 7

<211> 20

<212> DNA

<213> Homo sapiens

<400> 7

tgccttgacag agaagttgtc

20

<210> 8

<211> 20

<212> DNA

<213> Homo sapiens

<400> 8

cgggcacgtg gtgagtcacc

20

shardna.ST25.txt

<210> 9

<211> 20

<212> DNA

<213> Homo sapiens

<400> 9

tttccttcag cttacagaca

20

<210> 10

<211> 20

<212> DNA

<213> Homo sapiens

<400> 10

ccaaatgcct gtatgtatgt

20

<210> 11

<211> 20

<212> DNA

<213> Homo sapiens

<400> 11

ccctctgtag aagccgaggg

20

<210> 12

<211> 20

<212> DNA

<213> Homo sapiens

<400> 12

agctgttaag aattcctgct

20

<210> 13

<211> 20

<212> DNA

<213> Homo sapiens

<400> 13

ttcctttcag agctggaaag

20

shardna.ST25.txt

<210> 14

<211> 20

<212> DNA

<213> Homo sapiens

<400> 14

ggaattggag gtaaagccac

20

<210> 15

<211> 20

<212> DNA

<213> Homo sapiens

<400> 15

ttatgactag gagtctgcga

20

<210> 16

<211> 20

<212> DNA

<213> Homo sapiens

<400> 16

tgagtaattt atttattaag

20

<210> 17

<211> 20

<212> DNA

<213> Homo sapiens

<400> 17

agctttgtaa gaagaggaag

20

<210> 18

<211> 20

<212> DNA

<213> Homo sapiens

shardna.ST25.txt

<400> 18
ctccataacc gtaagaaata

20

<210> 19

<211> 20

<212> DNA

<213> Homo sapiens

<400> 19
ttgttttttag atttttggcc

20

<210> 20

<211> 20

<212> DNA

<213> Homo sapiens

<400> 20
gctactgcag gtgaatactc

20

<210> 21

<211> 20

<212> DNA

<213> Homo sapiens

<400> 21
tattttacag gaattggccc

20

<210> 22

<211> 20

<212> DNA

<213> Homo sapiens

<400> 22
ctgtctccag gtaaattccc

20

<210> 23

<211> 20

<212> DNA

<213> Homo sapiens

shardna.ST25.txt

<400> 23
attatttctag gtgctggaat

20

<210> 24

<211> 20

<212> DNA

<213> Homo sapiens

<400> 24
caaaaacaag gtaagtcagt

20

<210> 25

<211> 20

<212> DNA

<213> Homo sapiens

<400> 25
ttccacaaag tcaacacatc

20

<210> 26

<211> 20

<212> DNA

<213> Homo sapiens

<400> 26
tcaattcaag gtcatttttg

20

<210> 27

<211> 20

<212> DNA

<213> Homo sapiens

<400> 27
tctgttttcag gatttagcca

20

<210> 28

<211> 20

<212> DNA

shardna.ST25.txt

<213> Homo sapiens

<400> 28
actttgagag gtgggtgtcc

20

<210> 29

<211> 20

<212> DNA

<213> Homo sapiens

<400> 29
atctctgcag agaaagtgtc

20

<210> 30

<211> 20

<212> DNA

<213> Homo sapiens

<400> 30
tgtgtgattg gtaagaattt

20

<210> 31

<211> 20

<212> DNA

<213> Homo sapiens

<400> 31
gtcttcatag gcaaattgac

20

<210> 32

<211> 20

<212> DNA

<213> Homo sapiens

<400> 32
tacacagtgt atacagtttt

20

<210> 33

<211> 407

shardna.ST25.txt

<212> PRT

<213> Homo sapiens

<400> 33

Met Gln Gln Lys Ala Phe Glu Glu Ser Arg Tyr Pro Trp Gln Glu Ser
 1 5 10 15
 Phe Glu Asn Val Ala Val Cys Leu Pro Leu Arg Cys Pro Arg Cys Gly
 20 25 30
 Asp His Thr Arg Phe Arg Ser Leu Ser Ser Leu Arg Ala His Leu Glu
 35 40 45
 Phe Ser His Ser Tyr Glu Glu Arg Thr Leu Leu Thr Lys Cys Ser Leu
 50 55 60
 Phe Pro Ser Leu Lys Asp Thr Asp Leu Val Thr Ser Ser Glu Leu Leu
 65 70 75 80
 Lys Pro Gly Lys Leu Gln Ser Ser Gly Asn Val Val Lys Gln Lys Pro
 85 90 95
 Ser Tyr Val Asn Leu Tyr Ser Ile Ser His Glu His Ser Lys Asp Arg
 100 105 110
 Lys Pro Phe Glu Val Val Ala Glu Arg Pro Val Ser Tyr Val Gln Thr
 115 120 125
 Tyr Thr Ala Met Asp Leu His Ala Asp Ser Leu Asp Gly Thr Arg Ser
 130 135 140
 Gly Pro Gly Leu Pro Thr Ser Asp Thr Lys Ala Ser Phe Glu Ala His
 145 150 155 160
 Val Arg Glu Lys Phe Asn Arg Met Val Glu Ala Val Asp Arg Thr Ile
 165 170 175
 Glu Lys Arg Ile Asp Lys Leu Thr Lys Glu Leu Ala Gln Lys Thr Ala
 180 185 190
 Glu Leu Leu Glu Val Arg Ala Ala Phe Val Gln Leu Thr Gln Lys Lys
 195 200 205
 Gln Glu Val Gln Arg Arg Glu Arg Ala Leu Asn Arg Gln Val Asp Val
 210 215 220
 Ala Val Glu Met Ile Ala Val Leu Arg Gln Arg Leu Thr Glu Ser Glu
 225 230 235 240

shardna.ST25.txt

Glu Glu Leu Leu Arg Lys Glu Glu Glu Val Val Thr Phe Asn His Phe
 245 250 255

Leu Glu Ala Ala Ala Glu Lys Glu Val Gln Gly Lys Ala Arg Leu Gln
 260 265 270

Asp Phe Ile Glu Asn Leu Leu Gln Arg Val Glu Leu Ala Glu Lys Gln
 275 280 285

Leu Glu Tyr Tyr Gln Ser Gln Gln Ala Ser Gly Phe Val Arg Asp Leu
 290 295 300

Ser Gly His Val Leu Thr Asp Ile Ser Ser Asn Arg Lys Pro Lys Cys
 305 310 315 320

Leu Ser Arg Gly His Pro His Ser Val Cys Asn His Pro Asp Leu Lys
 325 330 335

Ser His Phe His Pro Lys Gly Arg Asn His Leu Lys Lys Ala Lys Asp
 340 345 350

Asp Arg Ala Ser Met Gln Pro Ala Lys Ala Ile His Glu Gln Ala Glu
 355 360 365

Ser Ser Arg Asp Leu Cys Arg Pro Pro Lys Lys Gly Glu Leu Leu Gly
 370 375 380

Phe Gly Arg Lys Gly Asn Ile Arg Pro Lys Met Ala Lys Lys Lys Pro
 385 390 395 400

Thr Ala Ile Val Asn Ile Ile
 405

<210> 34

<211> 333

<212> PRT

<213> Homo sapiens

<400> 34

Met Gln Gln Lys Ala Phe Glu Glu Ser Arg Tyr Pro Trp Gln Glu Ser
 1 5 10 15

Phe Glu Asn Val Ala Val Cys Leu Pro Leu Arg Cys Pro Arg Cys Gly
 20 25 30

Asp His Thr Arg Phe Arg Ser Leu Ser Ser Leu Arg Ala His Leu Glu
 35 40 45

shardna.ST25.txt

Phe Ser His Ser Tyr Glu Glu Arg Thr Leu Leu Thr Lys Cys Ser Leu
 50 55 60

Phe Pro Ser Leu Lys Asp Thr Asp Leu Val Thr Ser Ser Glu Leu Leu
 65 70 75 80

Lys Pro Gly Lys Leu Gln Ser Ser Gly Asn Val Val Lys Gln Lys Pro
 85 90 95

Ser Tyr Val Asn Leu Tyr Ser Ile Ser His Glu His Ser Lys Asp Arg
 100 105 110

Lys Pro Phe Glu Val Val Ala Glu Arg Pro Val Ser Tyr Val Gln Thr
 115 120 125

Tyr Thr Ala Met Asp Leu His Ala Asp Ser Leu Asp Gly Thr Arg Ser
 130 135 140

Gly Pro Gly Leu Pro Thr Ser Asp Thr Lys Ala Ser Phe Glu Ala His
 145 150 155 160

Val Arg Glu Lys Phe Asn Arg Met Val Glu Ala Val Asp Arg Thr Ile
 165 170 175

Glu Lys Arg Ile Asp Lys Leu Thr Lys Glu Leu Ala Gln Lys Thr Ala
 180 185 190

Glu Leu Leu Glu Val Arg Ala Ala Phe Val Gln Leu Thr Gln Lys Lys
 195 200 205

Gln Glu Val Gln Arg Arg Glu Arg Ala Leu Asn Arg Gln Val Asp Val
 210 215 220

Ala Val Glu Met Ile Ala Val Leu Arg Gln Arg Leu Thr Glu Ser Glu
 225 230 235 240

Glu Glu Leu Leu Arg Lys Glu Glu Glu Val Val Thr Phe Asn His Phe
 245 250 255

Leu Glu Ala Ala Ala Glu Lys Glu Val Gln Gly Lys Ala Arg Leu Gln
 260 265 270

Asp Phe Ile Glu Asn Leu Leu Gln Arg Val Glu Leu Ala Glu Lys Gln
 275 280 285

Leu Glu Tyr Tyr Gln Ser Gln Gln Ala Ser Gly Phe Val Arg Asp Leu
 290 295 300

Ser Gly His Val Ser Trp Lys Gly Ala Gly Glu Ala Arg Leu Val Cys
 305 310 315 320

shardna.ST25.txt
 Gln Asn Asp Leu Glu Leu Glu Glu Ser Ala Ile Val Glu
 325 330

<210> 35

<211> 462

<212> PRT

<213> Homo sapiens

<400> 35

Met Gln Gln Lys Ala Phe Glu Glu Ser Arg Tyr Pro Trp Gln Glu Ser
 1 5 10 15

Phe Glu Asn Val Ala Val Cys Leu Pro Leu Arg Cys Pro Arg Cys Gly
 20 25 30

Asp His Thr Arg Phe Arg Ser Leu Ser Ser Leu Arg Ala His Leu Glu
 35 40 45

Phe Ser His Ser Tyr Glu Glu Arg Thr Leu Leu Thr Lys Cys Ser Leu
 50 55 60

Phe Pro Ser Leu Lys Asp Thr Asp Leu Val Thr Ser Ser Glu Leu Leu
 65 70 75 80

Lys Pro Gly Lys Leu Gln Ser Ser Gly Asn Val Val Lys Gln Lys Pro
 85 90 95

Ser Tyr Val Asn Leu Tyr Ser Ile Ser His Glu His Ser Lys Asp Arg
 100 105 110

Lys Pro Phe Glu Val Val Ala Glu Arg Pro Val Ser Tyr Val Gln Thr
 115 120 125

Tyr Thr Ala Met Asp Leu His Ala Asp Ser Leu Asp Gly Thr Arg Ser
 130 135 140

Gly Pro Gly Leu Pro Thr Ser Asp Thr Lys Ala Ser Phe Glu Ala His
 145 150 155 160

Val Arg Glu Lys Phe Asn Arg Met Val Glu Ala Val Asp Arg Thr Ile
 165 170 175

Glu Lys Arg Ile Asp Lys Leu Thr Lys Glu Leu Ala Gln Lys Thr Ala
 180 185 190

Glu Leu Leu Glu Val Arg Ala Ala Phe Val Gln Leu Thr Gln Lys Lys
 195 200 205

shardna.ST25.txt

Gln Glu Val Gln Arg Arg Glu Arg Ala Leu Asn Arg Gln Val Asp Val
 210 215 220
 Ala Val Glu Met Ile Ala Val Leu Arg Gln Arg Leu Thr Glu Ser Glu
 225 230 235 240
 Glu Glu Leu Leu Arg Lys Glu Glu Glu Val Val Thr Phe Asn His Phe
 245 250 255
 Leu Glu Ala Ala Ala Glu Lys Glu Val Gln Gly Lys Ala Arg Leu Gln
 260 265 270
 Asp Phe Ile Glu Asn Leu Leu Gln Arg Val Glu Leu Ala Glu Lys Gln
 275 280 285
 Leu Glu Tyr Tyr Gln Ser Gln Gln Ala Ser Gly Phe Val Arg Asp Leu
 290 295 300
 Ser Gly His Val Ser Trp Lys Gly Ala Gly Glu Ala Arg Leu Val Cys
 305 310 315 320
 Gln Asn Asp Leu Glu Leu Glu Ile Phe Gly His Ile Asn His His Leu
 325 330 335
 Ser Gly Leu Lys Asp Ser His Cys Leu Val Phe Leu Gln Ala Pro Pro
 340 345 350
 Val Pro Trp Ile Ile Leu Ala Ser Phe Leu Trp Ile Leu Gly Asn Pro
 355 360 365
 Trp Thr Ser Ser Thr Ala Thr Ala Gly Phe Ser Gln Ile Trp Val Leu
 370 375 380
 Phe Pro Phe Cys Gly Gly Thr Phe His His Asn Glu Lys Asp Val Leu
 385 390 395 400
 Gly Leu Gln Asp Phe Glu Arg Glu Ser Val Ser Thr Ser Gln Ser Arg
 405 410 415
 Asn Ile Ser Leu Leu Thr Leu Gly Gln Leu Gln Asn Cys Val Ile Gly
 420 425 430
 Lys Leu Thr Ile Ile Asp Leu Leu Thr Glu His Leu Leu Gly Val Arg
 435 440 445
 His Gly Val Ile Cys Phe Pro Trp Gly Leu Pro Ser Ser Ser
 450 455 460

<210> 36

<211> 216

shardna.ST25.txt

<212> PRT

<213> Homo sapiens

<400> 36

Met Ser Ala Leu Gly Gln Ile Thr Ile Thr Val Ser Arg Cys Trp Asn
1 5 10 15

Thr Glu Arg Asn Gln Thr Asp Lys Asn Pro Cys Leu His Gly Ala Tyr
20 25 30

Leu Gln Leu Arg Glu Thr Val Lys Asn Lys Ser Thr His Leu Lys Lys
35 40 45

Pro Leu Met Lys Gln Ala Pro Pro Trp Lys Asp His Leu Ala Phe Gln
50 55 60

Pro Leu His Pro Ala Glu Arg Lys Thr Gln Val Trp Arg Trp Gln Ser
65 70 75 80

Gly Asn Ser Ser Asp Leu Glu Thr Thr Ser Ser Ala Ser Pro Trp Pro
85 90 95

Thr Gly Ser Asn Arg Asp Val Val Leu Asn Thr Leu Ala Glu Ser Cys
100 105 110

Cys Gly Leu Ser Glu Leu Ile Thr Ala Pro Pro Tyr Ala Gly Val Ser
115 120 125

Ile Gln Gly Phe Ser Gln Ile Trp Val Leu Phe Pro Phe Cys Gly Gly
130 135 140

Thr Phe His His Asn Glu Lys Asp Val Leu Gly Leu Gln Asp Phe Glu
145 150 155 160

Arg Glu Ser Val Ser Thr Ser Gln Ser Arg Asn Ile Ser Leu Leu Thr
165 170 175

Leu Gly Gln Leu Gln Asn Cys Val Ile Gly Lys Leu Thr Ile Ile Asp
180 185 190

Leu Leu Thr Glu His Leu Leu Gly Val Arg His Gly Val Ile Cys Phe
195 200 205

Pro Trp Gly Leu Pro Ser Ser Ser
210 215

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)